Additional file 2 of Differences in oxylipin profile in psoriasis versus psoriatic arthritis

Additional file 2: Supplementary Table 1. Characteristics of PsO patients with low (PASI ≤ 2.5) and high (PASI > 2.5) skin disease activity. Supplementary Table 2. Comparison of oxylipins between PsO patients with low (PASI ≤ 2.5) and high (PASI > 2.5) skin disease activity. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 3. Correlation of oxylipins with PASI in PsO patients. The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 4. Correlation of oxylipins with BMI in PsA patients. The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 5. Characteristics of PsA patients with low (PASI ≤ 2.5) and high (PASI > 2.5) skin disease activity. Supplementary Table 6. Comparison of oxylipins in PsA patients with high (PASI > 2.5) versus low (PASI ≤ 2.5) skin disease activity. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 7. Correlation of oxylipins with PASI in PsA patients. The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 8. Comparison of oxylipins in patients with high (PASI > 2.5) versus low (PASI ≤ 2.5) skin disease activity (both cohorts combined). The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 9. Correlation of oxylipins with mNAPSI (both cohorts combined). The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 10. Comparison of oxylipins between patients with cDAPSA 13. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 11. Comparison of oxylipins between PsA patients with cDAPSA